Blockchain Registration Transaction Record

Oragenics Advances Intranasal Brain Therapy for Concussion Toward Phase 2 Trials

Oragenics advances ONP-002, an intranasal neurosteroid for concussion treatment, toward Phase 2 trials in 2026. Learn about this potential first-in-class therapy and its impact on neurological care.

This development matters because concussion and mild traumatic brain injury affect millions globally, often leading to long-term cognitive and neurological issues without effective pharmacological treatments. Oragenics' ONP-002, as a potential first-in-class therapy, could address a significant unmet medical need, offering a non-invasive intranasal option that may improve recovery outcomes and quality of life for patients. Beyond concussion, the technology's applications in conditions like Alzheimer's and Parkinson's disease highlight its broader impact on neurological care, potentially transforming treatment paradigms and reducing healthcare burdens. For investors and the biotech industry, it represents a promising advancement in drug delivery and neurotherapeutics, with implications for future innovations in brain health.